Home » Topics » Disease categories and therapies » Hematologic

Hematologic
RSS

Isis Pharmaceuticals reports data for ISIS-FXI-Rx in prevention of venous thrombosis

May 26, 2014

Sanofi divulges novel P2Y12 receptor antagonists for thrombotic disorders

May 23, 2014

GlycoMimetics receives payment from Pfizer in connection with phase III trial

May 22, 2014

Isis Pharmaceuticals begins phase I study of ISIS-PKK-Rx

May 21, 2014

Portola Pharmaceuticals starts enrollment in phase III study of andexanet alfa and Xarelto

May 16, 2014

Apitope begins preclinical development for ATX-F8-117

May 9, 2014

Bristol-Myers Squibb discloses novel coagulation factor XIa inhibitors

May 8, 2014

Novel thrombin inhibitors disclosed by Merck & Co. and Albany Molecular Research

May 7, 2014

Alexion achieves regular approval for Soliris in aHUS

May 6, 2014

Bristol-Myers Squibb describes novel FXIa inhibitors

May 6, 2014

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan. 27, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for January 27, 2025
New drugs with the same old resistance tricks?
BioWorld
According to the World Health Organization (WHO), multidrug-resistant pathogens caused over 1.27 million deaths worldwide in 2020. And figures are rising, with...
OS Therapies heading to FDA with positive osteosarcoma data
BioWorld
With positive data in hand from its phase IIb trial testing immunotherapy candidate OST-HER2 in osteosarcoma, OS Therapies Inc. anticipates a regulatory filing...
Vilastobart set apart? Xilio phase II combo performs in CRC
BioWorld
“The [colorectal cancer field is moving, and thankfully it’s moving quickly,” said Marwan Fakih, gastrointestinal specialist at City of Hope, speaking about...